Table 1.
The identified 17 small molecules, their optimal doses, mechanisms of action, and ACE2 expression levels in each cell type.
| Drug name (uM) | Mechanism of action | Cell type | ||||
|---|---|---|---|---|---|---|
| A549 | CORL23 | H1299 | NCIH596 | SKLU1 | ||
| Acetylcysteine (0.01) | Mucolytic agent | −2.29 | ||||
| CD-437 (0.1) | Retinoid receptor agonist | −1.74 | ||||
| NVP-BEZ235 (0.0316) | mTOR inhibitor, PI3K inhibitor | −1.47 | ||||
| Amifostine (0.3162) | Reducing agent | −1.47 | ||||
| Ingenol (0.01) | PKC activator | −1.45 | No data | |||
| NVP-AUY922 (0.1) | HSP inhibitor | −1.41 | ||||
| Tretinoin (0.3162) | Retinoid receptor agonist, retinoid receptor ligand | −1.40 | ||||
| Sulforaphane (0.001) | Anticancer agent, aryl hydrocarbon receptor antagonist | −1.32 | ||||
| Bortezomib (0.0316) | NFkB pathway inhibitor, proteasome inhibitor | −0.54 | 0.13 | 0.13 | −0.80 | −0.96 |
| Parbendazole (0.3162) | Tubulin polymerization inhibitor | −0.53 | 0.01 | 0.80 | −0.80 | −0.09 |
| Idarubicin (0.1) | Topoisomerase inhibitor | −0.47 | 0.70 | −1.44 | 0.00 | 0.46 |
| Tanespimycin (0.3162) | HSP inhibitor | −0.23 | 0.00 | 0.09 | 0.39 | 0.07 |
| SN-38 (0.3162) | Topoisomerase inhibitor | −0.19 | −0.37 | −0.55 | −0.38 | 0.20 |
| FK-866 (0.1) | Niacinamide phosphoribosyltransferase inhibitor | 0.06 | −0.79 | 0.41 | −0.50 | 0.10 |
| Gemcitabine (0.1) | Ribonucleotide reductase inhibitor | 0.09 | 0.63 | 0.94 | 0.50 | −1.28 |
| YM-155 (0.3162) | Survivin inhibitor | 0.36 | 0.00 | −0.82 | −0.57 | −0.17 |
| PIK-75 (0.1) | DNA protein kinase inhibitor, PI3K inhibitor | 2.32 | 0.45 | −1.04 | 0.54 | −0.37 |
The small molecules are sorted based on the ACE2 expression levels in A549. The numbers in brackets beside drug names are their optimal dosages (μM). Gray area means no data in the preprocessed dataset.